Advanced or metastatic renal cell carcinoma
Ipsen Biopharmaceuticals Canada Inc.
Call for patient/clinician input open:
Call for patient/clinician input closed:
Manufacturer Requested Reimbursement Criteria1:
Cabometyx in combination with nivolumab for the first-line treatment of adult patients with advanced (not amenable to curative surgery or radiation therapy) or metastatic RCC.
Cabometyx in combination with nivolumab, is indicated for the first-line treatment of adult patients with advanced (not amenable to curative surgery or radiation therapy) or metastatic RCC
- The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of CADTH. Reimbursement criteria from CADTH will be documented in the final recommendation, if applicable.